As of August 2026, only one psychedelic-adjacent medication has received FDA approval for treating a psychiatric condition: esketamine (Spravato), approved for treatment-resistant depression and suicidal ideation. But the psychedelic medicine landscape is shifting rapidly, with psilocybin, MDMA, and LSD all progressing through late-stage clinical trials and regulatory reviews that could reshape mental health treatment within the next year.

What's the Current Status of Psychedelic Drugs in FDA Review?

Esketamine holds three separate FDA approvals: one from March 2019 for treatment-resistant depression (when combined with an oral antidepressant), another from August 2020 for major depression with acute suicidal ideation or behavior, and most recently, a January 2025 approval allowing it to be used as a monotherapy without a second antidepressant. The medication requires administration in a certified medical setting with at least two hours of observation afterward.

Psilocybin (COMP360) is the furthest along in the approval pipeline. Compass Pathways completed two positive Phase 3 trials: COMP005 in June 2025 and COMP006 in February 2026. The company is submitting its application to the FDA on a rolling basis, with the final module expected in the fourth quarter of 2026. If approved and the Drug Enforcement Administration (DEA) reschedules psilocybin, commercial launch is targeted for the first half of 2027. However, in a head-to-head trial against the antidepressant escitalopram, psilocybin did not show a significant advantage on the primary outcome measure, meaning the Phase 3 wins were against lower-dose control groups rather than against existing standard treatments.

MDMA-assisted therapy faced rejection in August 2024 after the FDA's advisory committee voted 9-2 that effectiveness was not established and 10-1 against the benefit-risk profile, citing concerns about trial unblinding and conduct issues. The sponsor, now called Resilient Pharmaceuticals, resubmitted the application in August 2026 under the proposed brand name Rysanso. Notably, the resubmission does not include a new efficacy trial; instead, it relies on a third-party audit of the original trials, a new Phase 1 cardiac safety study, and follow-up data from the Veterans Affairs (VA). The FDA is expected to make a decision on a roughly six-month review timeline from the August 2026 resubmission.

Which Psychedelic Drugs Are Closest to Approval?

LSD (now called DT120) is advancing rapidly through Phase 3 trials under Definium Therapeutics, formerly known as MindMed. The company announced positive Phase 3 results for two indications: Emerge for major depression (June 22, 2026) and Voyage for generalized anxiety disorder (August 12, 2026). Both results exist as company press releases and have not yet been published in peer-reviewed journals. A third Phase 3 trial, Panorama, is expected to read out around September 2026. The published evidence base consists of a Phase 2b study in JAMA, which was sponsor-funded.

DMT and related compounds are earlier in development. The most advanced program, BPL-003 (intranasal 5-MeO-DMT), showed positive Phase 2b results in July 2025 and is moving into Phase 3 planning with FDA guidance. VLS-01 (buccal DMT) is fully enrolled in Phase 2b with topline results expected in the fourth quarter of 2026. Ayahuasca itself has no FDA approval pathway in progress, though intranasal 5-MeO-DMT is pharmacologically distinct from ayahuasca.

Ibogaine remains the exception: there are no FDA efficacy trials underway, and all evidence is observational and self-selected, mostly gathered outside the United States. However, Texas passed legislation (SB 2308) signed on June 11, 2025, creating a $50 million matched public-private fund to advance ibogaine through FDA trials for opioid use disorder, post-traumatic stress disorder (PTSD), and traumatic brain injury (TBI). Until those trials begin, ibogaine has promising signals but no regulatory evidence of efficacy.

How to Understand FDA Breakthrough Therapy Designation

• What It Means: Breakthrough therapy designation speeds up FDA meetings and review logistics for drugs showing preliminary promise on serious conditions, but it does not guarantee approval or final efficacy confirmation.
• What It Doesn't Mean: The designation is often misread as near-approval. MDMA-assisted therapy held breakthrough designation from August 2017 and was rejected in 2024, demonstrating that the label offers no guarantee of eventual approval.
• How to Read It: When a press release leads with "FDA breakthrough therapy," interpret it as "the FDA agreed to talk faster," not "the FDA agreed the drug works."

Most of the drugs in the psychedelic pipeline hold breakthrough therapy designation, but this status reflects only preliminary promise, not a pathway to certain approval.

The psychedelic medicine field is moving from experimental research into regulatory reality. Esketamine's approvals have already changed clinical practice for treatment-resistant depression and suicidal crises. Psilocybin, MDMA, and LSD could follow within months to a year, pending FDA decisions and, in some cases, DEA rescheduling. However, the regulatory path remains uncertain: MDMA's resubmission without new efficacy data, psilocybin's mixed performance against existing antidepressants, and LSD's unpublished Phase 3 results all suggest that approval is not automatic, even for drugs with preliminary positive signals.